OnCo
peoplePerson

Shaji K. Kumar

Myeloma trialist who led venetoclax and quadruplet studies and helped define MRD response criteria.

Shaji Kumar is a haematologist leading myeloma clinical research at Mayo Clinic Rochester. Chaired BELLINI (venetoclax in t(11;14) myeloma), co-authored the IMWG response and MRD criteria, and leads ECOG-ACRIN myeloma trials.

Role
Professor of Medicine; Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo Clinic
Institution
Mayo Clinic
Specialisms
Multiple myelomaClinical trialsMRD

Papers

2top
TitleJournalYear
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaLancet Oncology2016
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialLancet Oncology2020

Connected

6top

cancers

1
Multiple myeloma

technologies

1
MRD / molecular residual disease testing

drugs

1
ApprovedSmall-molecule BCL-2 inhibitor
Venetoclax · Venclexta

institutions

2
ECOG-ACRIN Cancer Research GroupMayo Clinic

terms

1
MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)